China’s Strategies to Keep Its Population Employed: Keep Exports High, Find External Bogeymen, Employ in the Army
China and U.S. Superpowers
How Will Their Relationship Shape the Future World Economy?
By Catherine Austin Fitts
The U.S. is exporting inflation—planning for a tsunami of digital tokens and stablecoins while engineering a closed energy control war against China. Meanwhile, China is leading a manufacturing automation, transportation, and AI export juggernaut that has the potential to be highly deflationary. Exactly how is all of this supposed to work?
Full report: solari.com/china-and-u-s-sup…
Subscribe: shop.solari.com
1.) Download - xferchain.net/#download (This is software that runs a node once signed in, called your Heartbeat)
2.) Sign-In with X account
3.) As long as node is running, and you have a blue check on your X account, then you are eligible. Every Minute to WIN 5,000 #XFER
The ZKP Migration App is available for retail holders moving ZIL from a Legacy (zil1...) account to a Zilliqa EVM (0x...) account.
Our guide covers setup on Windows and Linux, the steps in the app, and how to complete the claim.
Read it before starting: blog.zilliqa.com/migrate-zil…
A quick ZIL migration update:
- @binance has announced support for the ZIL token migration binance.com/en/support/annou….
- @bitvavocom and @MEXC have resumed ZIL deposits and withdrawals on Zilliqa EVM.
- The ZKP migration tool is in its final stages of preparation. It will be released soon.
- The second exchange migration hard fork was successfully activated on 22nd September at block height 36,383,378. ZIL balances for participating exchanges were migrated from legacy Schnorr addresses to verified Zilliqa EVM addresses.
- Participating exchanges are expected to restore ZIL deposits and withdrawals gradually on Zilliqa EVM. Please follow their official channels for timeline.
Elon could also be speaking about @XCoinTokenize
▪️New fair launched fork of Ravencoin (9/12/2026)
▪️Tokenization of X accounts
▪️Send / Receive tokenized assets via X handles
▪️Cost to 'mine': Your verified X account
🔜 Decentralization from "X-only"
🔜 Custom Asset Exchange
Just a quick update on @NeoxaPortal DEX that is currently in closed beta testing since I haven't posted anything in a while about the DEX. The Dev(s) are currently doing some rewrites to speed up transactions but it's getting closer. So I still have hopes for Oct release.
BREAKING STUDY: Nattokinase Breaks Down SPIKE PROTEIN, AMYLOID MICROCLOTS, BLOOD CLOTS, and SHRINKS ARTERIAL PLAQUE
We assembled DECADES of evidence to uncover the powerful MULTI-TARGET EFFECTS of nattokinase:
- Degrades spike protein
- Breaks down harmful amyloid proteins
- Dissolves abnormal amyloid microclots
- Breaks down fibrin blood clots
- Boosts the body’s natural clot-dissolving system
- Shrinks arterial plaque
- Lowers blood pressure
- Reduces blood-clotting factors and platelet clumping
Our new paper, “Proteolytic Targets and Clinical Benefits of Oral Nattokinase: Spike Protein and Amyloid Degradation, Fibrinolysis, and Cardiovascular Risk Reduction,” was produced through a collaboration between The Wellness Company and the McCullough Foundation.
It represents one of the most comprehensive evaluations of nattokinase to date, uniquely integrating its proteolytic, cardiovascular, pharmacokinetic, amyloid, and spike-protein literature into a single paper.
After oral dosing, nattokinase-related activity shows up in human blood and changes clotting and clot-breakdown markers within hours.
Three independent labs have now shown that nattokinase-related enzymes can BREAK DOWN SPIKE PROTEIN in vitro—including purified nattokinase itself.
At higher doses, human imaging studies reported about a 36% SHRINKAGE in carotid artery plaque—suggesting the effective range may begin around 6,000 FU/day.
Randomized human trials also show modest BLOOD-PRESSURE reductions with nattokinase, with pooled decreases of about 3.5 mmHg systolic and 2.3 mmHg diastolic.
And in long-term population studies, higher natto intake was associated with a 25% LOWER RISK of cardiovascular death and a 32% LOWER RISK of stroke death.
Nattokinase has been well tolerated across human studies, with no notable adverse events reported across six randomized trials. Even 10,800 FU/day for 12 months was used in a large observational cohort without reported excess bleeding.
This inexpensive, orally available enzyme holds immense promise for cardiovascular risk reduction in the post-COVID era.
It now deserves large-scale clinical testing for cardiovascular risk reduction and other post-vaccination injury applications.
We plan to launch some of these studies shortly.
@twc_health@McCulloughFund@P_McCulloughMD@DrHarveyRisch@DrKellyVictory@jathorpmfm@drdrew@PeterGillooly
neoxanodes.com offers cheap and easy hosting service for your $NEOX smart nodes (master nodes) for as little as $0.60 monthly ($0.02 daily). Running a SN gives you 1,500 $NEOX every ~3 days and voting rights. neoxanodes.com/